H107e/CAF10b

Phase of Development

Phase 1

Vaccine Platform

Protein / Adjuvant

Candidate Overview

H107e/CAF®10b is being developed by SSI and is a next-generation TB subunit vaccine incorporating 8 different Mtb antigens in a novel liposomal Th1/Th17 inducing adjuvant. It is specifically designed to complement a BCG response with novel T cells against Mtb-specific antigens and comes with the option of BCG co-administration.

Sponsor / Lead Developer: Statens Serum Institut

Clinical Trial Status: Active Trials

Primary Indication: Prevention of TB disease

Target Population(s): Adolescents, Adults, Infants, People living with HIV, People with Mtb infection, and People without Mtb infection

Target Route of Administration: Intramuscular

Clinical Trials

ACTIVE TRIALS
Registry NumberNCT06050356
Clinical Trial PhasePhase 1
Clinical Trial SponsorStatens Serum Institute
Primary endpoint(s) for this clinical trialSafety
Immunogenicity
Target population(s) for clinical trialAdults
People with Mtb infection
People without Mtb infection

Related Publications

  1. A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG. (NPJ Vaccines, 2023)
  2. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin. (Nat Commun., 2021)

Source: Vaccine Sponsor

Date Updated/Reviewed: 15-Dec-2023